Topic Archives: ovarian cancer

Comments

  • Avatar

    I got the privilege of watching ovarian cancer take the life of my older sister. She didn't smoke, watched what she ate,...

  • Avatar

    In 1975 Dr Richardson treated my mother, who had stage 4 ovarian cancer. The Laetrile made her vomit blood and rapid...

  • Dr. KSS MD PhD

    Be clear on this: NK cells are part of the INNATE immune system. But unless they work 100 percent and fully, tumors rela...

  • Avatar

    $Ovarian Cancer. Wow, early detections would be a godsend for all cancers, especially Ovarian cancer (OC). Terrible di...

  • Avatar

    $VBLT VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cance...

  • SoGiAm

    $FATE long - Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Can...

  • Avatar

    I have a friend who rejected chemo/traditional treatment and went on Dr. Gonzalez's regimen some 20 years ago for her ov...

  • Avatar

    NP $ VBLT 07:01 VBLT Vascular Biogenics announces that the EMA has designated ofranergene obadenovec (VB-11...

  • SoGiAm

    $FATE long - Fate Therapeutics Reports Second Quarter 2017 Financial Results http://ir.fatetherapeutics.com/releasede...

  • Avatar

    $VBLT ow position VBLT had its quarterly conference call today. Here are some highlights. The only thing I found ...

  • Avatar

    Good Dr. Interesting that you cite IPIX's (formerly CTIX) Kevetrin, which the FDA gave Orphan Drug designation to IPI...

  • Avatar

    My mom was a almost a 20.year ovarian cancer survivor..She was the bad ass in family. Always with grace. She outlive my ...

  • Dr. KSS MD PhD

    Hi Ron: Thanks for posting this. I had a look at Oncolix, whose lead agent is a single amino acid substituted protein th...

  • Avatar

    About $AEPP sp, Oncolix, and $ARTH fp Many thanks, Doc, for your new column….since reading it last evening ...

  • Avatar

    I need to take my daughter to the dentist, but wanted to throw this out there--yesterday (or this morning?) $VBLT releas...

  • achandra13

    $VBLT np – The data looks good. Dr. KSS when you get time, would love to hear your take on it. For both rGBM and Ovari...

  • Avatar

    $CLVS $TSRO #PARP Hi Doc, I beg to differ - just slightly - with regard to your statement that "The agent (Clovis' ru...

  • Dr. KSS MD PhD

    $CLVS became the hottest takeout target in oncology this morning by announcing phase 3 data for PARPi rucaparib. The age...

  • Avatar

    $BIOC I think it's completely justified to be disappointed at the slow uptake since last years big jump. So far, it ap...

  • Avatar

    $TSRO - former long. *DJ TESARO Announces Availability of Zejula (Niraparib) for Patients With Recurrent Ovarian Cancer ...

  • Dr. KSS MD PhD

    RVW: be careful. First $TLOG may be planning to reverse merge....I'm not sure. Second, I have concerns this is not exact...

  • Avatar

    $CTIX SMALL LONG BEVERLY, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (the Compan...

  • Avatar

    TESARO (TSRO) Announces FDA Approval of its PARP Inhibitor, ZEJULA, for Treatment of Women With Recurrent Ovarian Cancer...

  • achandra13

    $TSRO TESARO Announces U.S. FDA Approval Of ZEJULA(TM) (Niraparib) For Women With Recurrent Ovarian Cancer TESARO A...

  • Avatar

    $TSRO $CLVS $AZN SunTrust analyst just issued a research report on the competitive scene of PARP inhibitors: "TESA...

  • Anamorph

    $TSRO long It appears, as so often in bio, that this company's SP is reacting to news about a competitor. Astra-Ze...

  • Avatar

    I've done a little research on my own and the company doing the most research and development on gold protocal cancer tr...

  • Dr. KSS MD PhD

    Thanks for posting. I predict failure for this trial. You'd have to know the pathways and the molecular genetics, but pl...

  • Avatar

    $AZN $JNJ $NVS $PFE $NVO $RHHBY $GSK $TEVA $BIIB $LLY $TSRO $NBIX $KITE $PBYI *The top 15 would-be blockbusters in t...

  • Avatar

    $SNDX Syndax anticipates making a go/no go decision to progress into the second stage for each arm of ENCORE 601 in the...

  • Avatar

    $VBLT: VBL Therapeutics Provides Year End 2016 Corporate Update January 9, 2017 TEL AVIV, Israel, Jan. 09, 2017 (...

  • Avatar

    STM: Please don't rush out to sell your $CLVS yet...the company did win an early approval on December 18, 2016 for its P...

  • Avatar

    re: Holdings. Thanks for both the initial suggestions and the offer to provide more granular feedback. I'll be the f...

  • analog68

    $CLVS np but order in during halt! FDA approves ovarian cancer treatment Rubraca Looking to scalp this today only....

  • Dr. KSS MD PhD

    $TSRO yes. I admit Tesaro kind of caught me napping. The problem is PARP inhibitors, which Tesaro has. There have been S...

  • Avatar

    As a $TSRO shareholder, I can share some of my experience.On June 30th Tesaro did a similar secondary (pricing and total...

  • arch1

    J&J talc suit news; Short URL| Email Article| Comment| Contact| Print| A A After a $67.5 million jury verdic...

  • Avatar

    Unfortunately most mistakes are covered up and unreported. I had an older sister that didn't smoke or drink, ate the rig...

  • Dr. KSS MD PhD

    Very dazzling performance especially in ovarian cancer, with nearly half of all patients responding in some fashion. Ver...

  • Avatar

    $GILD $TSRO: I'd like to offer an alternative view: when and if Gilead makes a major move in acquisition, its growth...

  • SoGiAm

    Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research P...

  • Dr. KSS MD PhD

    This is in response to linling, who wrote last night asking about PARP inhibitors and the companies advancing them, such...

  • Avatar

    $BIOC no position. A company listed in London, ANGLE plc (AGL) and on OTC-QX (ANPCY), claims its ParsortixTM microfluidi...

  • Avatar

    Very nice and useful article Doc, thanks so much. As far as what a SPA means here is a link that explains thoroughly wha...

  • Avatar

    It is with profound interest to learn about this new Magic $1 Pill, so much so, I decided to subscribe to become a membe...

  • Avatar

    Recent advances in treating Ovarian Cancer. http://blog.aacr.org/recent-advances-treating-ovarian-cancer/ Cheers,G...

  • Avatar

    I joined a trading app called Robinhood.com. I put $2000 in there. Had to wait 3 days for it to become active. Today I b...

  • Dr. KSS MD PhD

    I must admit I am disappointed at the relative lack of compellingness of the literature I have found on the talc/ovary c...

  • Dr. KSS MD PhD

    Epidemiology of talc and ovarian cancer http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820665/ http://www.ncbi.nlm.nih.g...

  • Anamorph

    Doc, please let us know about the studies that do link talc with ovarian cancer, as what I am seeing does not point that...

  • Dr. KSS MD PhD

    Sharon: I say this just trying to have your back covered because I care about what happens to your investments: I agree ...

  • arch1

    Seems safest bet is don't dust the rug. My mother died of ovarian cancer and i remember her being in clouds of talcum c...

  • Avatar

    JNJ: The International Agency for Research on Cancer (IARC) is part of the World Health Organization (WHO). Its major go...

  • Avatar

    Johnson and Johnson: Second woman awarded $86mil as baby powder can cause ovarian cancer. Anyone who is still long sho...

  • Avatar

    My mom had ovarian cancer in the early 90's. They did a hysterectomy.. then radiation.. She made it 18 years after..(whi...

  • Avatar

    interesting Stem Cell studies released today in Prostate and Ovarian Cancer. http://journals.lww.com/oncology-times/blo...

  • Avatar

    I am a medical practitioner. I look at this drug from a different perspective than I have been reading out there in 'te...

  • achandra13

    $CTIX Cellceutix meets fda phase-2 clinical trial kevetrin ovarian cancer http://seekingalpha.com/pr/16152296-cellceut...

  • Avatar

    For those still in $CTIX,: Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer...

  • Avatar

    Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer BEVERLY, MA--(Marketw...

  • Avatar

    Ovarian cancer drug shows promise with prostate cancer. http://www.ptcommunity.com/news/2015-10-29-000000/ovarian-can...

  • Avatar

    $CTIX: Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines ...

  • Avatar

    This New York Times article is important reading, particularly if you know someone with ovarian cancer. A treatment w...

  • Dr. KSS, MD PhD

    A fascinating report out of MD Anderson this morning: among women with ovarian cancer who take beta-blockers for any ind...

  • Dr. KSS, MD PhD

    Peering in at mid-day to answer Glenn's question about Oxigene, a $36M South San Francisco company that has stayed liste...

  • Avatar

    Doc Kss,when you get a chance could I get your thoughts on this company Oxigene(OXGN) and their drug ZYBRESTAT working w...

  • Avatar

    This company looks interesting Vermillion (VRML) with their OVA1 diagnostic blood test for pre-surgical assessment of ov...

  • Dr. KSS, MD PhD

    Obviously if you're in $CTIX here, hold. But the casus diabli is this. Kevetrin is YEARS away from being proven to have ...

  • Avatar

    $CTIX Kevetrin granted Orphan Drug Designation for Ovarian Cancer yesterday. Here is the link: http://www.accessdata....

  • Avatar

    Yes, but for ovarian cancer, not breast...orphan drug designation made 7-14-15. Can't easily post a link right now but ...

  • Dr. KSS, MD PhD

    Hi Sharon: Yes, while cancers do have elaborate immune-deterrent mechanisms, as long as they have an exposed surface mem...

  • Avatar

    Good article. (The Scientist becomes the Survivor and Advocate) fighting ovarian cancer. http://blog.aacr.org/laura-sha...

  • Avatar

    I've been flat on my back for the last three days with the Cold from Hell. so if I reiterate other posting I apologize i...

  • Avatar

    Hi Dr. KSS I mentioned 2 days ago about PBMD and that it was up 200% from .50 cents. Now today it is at $5.65. th...

  • Avatar

    Wow! Thanks for the input, Pat -- I bought a few shares of PBMD to make it correct downward. Positive phase II ovarian...

  • Avatar

    PBMD / just noticed the huge jump on this stock today, up over 200%. I am not a bio mind does anyone know anythin...

  • Vijay Panikar

    $KPTI. from leerink asco abstracts. • KPTI (OP): Ph II data for selinexor suggests single agent activity in solid...

  • Avatar

    Doc KSS, this company Novogen (NVGN) appear to have some very nice pre-clinical work in oncology and were once merged wi...

  • sogiam

    $CTIX-e-mail Best2ALL!-Benjamin My Fellow Cellceutix Shareholders, We are pleased to inform you that Cellceutix Chie...

  • Avatar

    One promising area is turning on the body's own defense against cancer -- the p53 "guardian angel" gene. CTIX announced ...

  • Dr. KSS, MD PhD

    Diana, about $CTIX and your excellent comments above: (1) Personally I find Alexander's reassurances about the non-to...

  • Avatar

    Dr. thank you for the great continuing education about how to evaluate trial news and hypes! I listened again to the 201...

  • Dr. KSS, MD PhD

    I am putting $CTIX on notice: THIS kind of press release has no place, and if this sort of thing continues I am exiting....

  • Avatar

    Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Ant...

  • Avatar

    Northwest Biotherapeutic (NWBO) might deserve a mention in this list. NW Bio is Developing dendritic cell-based vaccines...

  • Avatar

    Scorpio, here is a link that works now: http://edge.media-server.com/m/p/ya62u49c Some new details fleshed out a little...

  • Dr. KSS, MD PhD

    Certain traders who need to lighten up on the benzedrine. People read a press release and seem to have flipped because t...

  • Dr. KSS, MD PhD

    It's a psychotic overreaction to news that is not bad. (1) the ovarian cancer is the least interesting of all TLOG stud...

  • sogiam

    TLOG-TetraLogic Provides Update on Ovarian Cancer Study 7:00a ET December 16, 2014 (GlobeNewswire) TetraLogic Pharmaceu...

  • Dr. KSS, MD PhD

    Mary was asking about Clovis $CLVS. I can't say I have found anything negative to explain the recent down move. I think ...

  • Avatar

    $CLVS update on ovarian cancer trial Clovis Oncology, Inc. has added a news release to its Investor Relations web...

  • Avatar

    Interesting bullish article today on SA regarding $CLVS by an author who I follow. One of the key theses is that a ovar...

  • Dr. KSS, MD PhD

    Will respond to more comments this evening, but one other thing in brief: Oxigene ($OXGN) recently presented data on its...

  • Dr. KSS, MD PhD

    Thomas: (1) keep in mind that phase 1 will have no data til fall 2016...2 years away! Unless it proves highly toxic. ...

  • Dr. KSS, MD PhD

    In my view, Atara is overpriced here. It appears to have only one agent in a phase 1 trial, one being studied in ovarian...

  • Dr. KSS, MD PhD

    Glenn asked last night about $PBMD Prima BioMed, an early stage Australian company that has just purchased Paris immunol...

  • Avatar

    Dr.KSS: Any thoughts on a new IPO called Atara Biotechnology $ATRA? Impressive management. Partnership with MSKCC in dev...

  • Avatar

    I wonder if those same families who are insisting that everything possible be done, would do so if at least some of the ...

  • Avatar

    JohnM: Thanks for those links. Very interesting info, especially the one referencing ovarian cancer connections. I fo...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch